10-K: Ovid Therapeutics Narrows 2025 Loss, Boosts Cash with New Funding

Ovid Therapeutics Inc. reported a reduced net loss for 2025, driven by increased revenue and successful capital raises, as it advances its pipeline of brain disorder treatments.

Summary

• Ovid Therapeutics Inc. reported a net loss of $17.4 million for the year ended December 31, 2025, a significant reduction from $26.4 million in 2024.
• Total revenue increased to $7.3 million in 2025 from $0.6 million in 2024, primarily due to a $7.0 million payment from an amendment to the Marinus License Agreement.
• Research and development expenses decreased to $25.6 million in 2025 from $36.8 million in 2024, mainly attributed to the pause of the OV888 (GV101) program.
• General and administrative expenses also decreased to $24.1 million in 2025 from $25.7 million in 2024, partly due to a 2024 organizational restructuring.
• Cash, cash equivalents, and marketable securities increased to $90.4 million as of December 31, 2025, up from $53.1 million in 2024.
• The company completed a private placement in October 2025, generating $75.1 million in initial net proceeds and potentially an additional $94.0 million from full warrant exercise.
• A subsequent private placement on March 17, 2026, is expected to generate $60.0 million in gross proceeds to support the expansion of OV329 development.
• OV329, a next-generation GABA-AT inhibitor, demonstrated a favorable safety profile and target engagement in a Phase 1 study, with plans to expand into Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS) in parallel to its Focal Onset Seizures (FOS) program.
• OV4071, an oral KCC2 direct activator, received regulatory approvals in Australia and is slated to initiate a Phase 1 clinical study in Q2 2026.
• The soticlestat program, previously co-developed with Takeda, was discontinued in January 2025 after failing to meet primary endpoints in Phase 3 trials, leading to a $30.0 million decrease in royalty monetization liability in 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting improved financial metrics, successful capital raises, and promising early-stage clinical progress for key pipeline assets, despite the setback with the soticlestat program and ongoing operational losses.

Positives

• Net loss significantly reduced to $17.4 million in 2025 from $26.4 million in 2024, indicating improved financial performance.
• Revenue increased substantially to $7.3 million in 2025 from $0.6 million in 2024, driven by a $7.0 million payment from the Marinus License Agreement amendment.
• Cash, cash equivalents, and marketable securities increased to $90.4 million by December 31, 2025, from $53.1 million in 2024, strengthening the liquidity position.
• Successful completion of a $75.1 million net proceeds private placement in October 2025, with potential for an additional $94.0 million from full warrant exercise.
• Secured an additional $60.0 million gross proceeds from a private placement on March 17, 2026, specifically for OV329 development expansion.
• OV329 Phase 1 study demonstrated a favorable safety profile, was well-tolerated with no serious adverse events, and showed encouraging signs of target engagement.
• Preclinical data for OV329 indicates it is 100-fold more potent than vigabatrin and does not accumulate in the retina, suggesting a differentiated safety profile.
• Regulatory discussions are underway for OV329's planned Phase 2 patient studies, and additive studies are launching to expand OV329 into TSC and IS.
• OV4071, an oral KCC2 direct activator, received Human Research Ethics Committee (HREC) approval and Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) acknowledgment for a Phase 1 clinical trial, expected to initiate in Q2 2026.
• The KCC2 direct activator portfolio represents a unique small molecule library with broad therapeutic potential in various brain disorders.
• Full recovery of $1.8 million from a fraudulent funds transfer in January 2025, which was previously recorded as a loss in 2024.
• The company's board of directors includes five out of seven independent members, providing strong governance oversight.

Negatives

• Continued operating losses, with an accumulated deficit of $321.7 million as of December 31, 2025.
• Discontinuation of the soticlestat program by Takeda in January 2025 after failing to meet primary endpoints in Phase 3 trials, leading to a $30.0 million decrease in the fair value of the royalty monetization liability in 2024.
• The OV888 (GV101) program is currently paused pending regulatory feedback on a competitive clinical-stage development program.
• The company's common stock experienced significant volatility, ranging from $0.26 to $1.84 per share in 2025, and a notable drop in June 2024 following the soticlestat Phase 3 results.
• The company was notified in February 2025 that its average closing bid price was below $1.00, requiring a transfer to the Nasdaq Capital Market, though compliance was regained by September 2025.
• The company had previously identified material weaknesses in internal control over financial reporting in Q3 2024 related to fund transfers and vendor updates, although these were remediated by December 31, 2024.
• The company's net operating loss (NOL) carryforwards are significantly limited by Section 382 ownership changes, potentially reducing their future utilization.

Risks

• The company will require additional capital to finance its operations, which may not be available on acceptable terms, if at all, potentially forcing delays or termination of drug development efforts.
• The company expects to continue incurring substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
• The company is early in its drug development efforts for current drug candidates, and all candidates are in clinical trials or preclinical development, carrying a high risk of failure.
• Results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, and drug candidates may not have favorable results in planned or future studies or may not receive regulatory approval.
• Drug candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial potential, or result in significant negative consequences following any potential marketing approval.
• If the market opportunities for drug candidates are smaller than believed, the business may suffer, requiring successful identification of patients and significant market share to achieve profitability and growth.
• The company faces substantial competition from major pharmaceutical and biotechnology companies with greater financial, technical, and human resources.
• Even if current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success.
• Inability to obtain and maintain patent protection for current or future drug candidates, or if the scope of patent protection is not sufficiently broad, may hinder competitive effectiveness.
• The company may be involved in product liability lawsuits, which could cause substantial liabilities and limit commercialization of any developed drug candidate.
• Reliance on third parties to produce clinical and commercial supplies of drug candidates and to conduct, supervise, and monitor preclinical studies and clinical trials introduces risks of unsatisfactory performance, delays, or quality issues.
• The company is highly dependent on the services of its senior management team and its ability to recruit and retain additional management, clinical, and scientific personnel.
• The company is exposed to the risk that its employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and insider trading.
• If information technology systems or data, or those of third parties, are compromised, the company could experience adverse impacts including regulatory investigations, litigation, fines, and interruptions to operations.
• The company is subject to stringent and evolving privacy and security laws, regulations, contractual obligations, and industry standards, and failure to comply could result in significant consequences.
• The company's ability to use its net operating loss (NOL) carryforwards and certain other tax attributes to offset future taxable income may be subject to limitation due to ownership changes.
• Changes in tax laws or regulations that are applied adversely to the company or its customers may have a material adverse effect on its business, cash flow, financial condition, or results of operations.
• The market price of the company's common stock has been and will likely remain volatile and fluctuate substantially, which could result in substantial losses for holders.
• Concentration of ownership of common stock among executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions.
• Provisions in the company's organizational documents and under Delaware law could make an acquisition of the company more difficult and may prevent attempts by stockholders to replace or remove current management.

Future Outlook

The company anticipates continued operating losses for the foreseeable future as it advances its drug candidates through preclinical and clinical development, seeks marketing approvals, and builds commercial infrastructure. It expects its cash, cash equivalents, and marketable securities as of December 31, 2025, combined with proceeds from the recent 2026 private placement, to fund operations for at least 12 months from the 10-K issuance date. The company plans to continuously review and modify its R&D and business development strategies based on scientific and clinical success and commercial potential. Future funding needs are expected to be met through equity and debt financings, strategic alliances, and licensing agreements.

Management Comments

• Our vision is to create sustained long-term value by advancing a differentiated pipeline of small molecule medicines intended to culminate in a fully integrated neurotherapeutics company with multiple clinical-stage programs and commercial medicines.
• We believe the lack of new classes of medicine in neurology and neuropsychiatry represents both an unmet need and a significant opportunity.
• We seek to develop medical therapies that are more efficacious and/or have gentler profiles for patients, meaning drugs that are intended to deliver preferable safety and tolerability profiles relative to approved drugs.
• Our near-term strategy is focused on clinical advancement of potential small molecule medicines to treat specific epilepsies and psychoses that are manifestations of neuronal excitatory/inhibitory imbalance.
• We believe that the benefits of these provisions [anti-takeover], including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.

Industry Context

StockSavvy.ai notes that Ovid Therapeutics operates in the highly competitive and fragmented fields of epilepsy and psychiatric medicines, which represent global market opportunities of approximately $8 billion and $22 billion, respectively. The regulatory environment appears increasingly amenable to new approaches, as evidenced by the FDA encouraging basket labels for Developmental and Epileptic Encephalopathies (DEEs) and the approval of a novel Mechanism of Action (MoA) therapeutic in schizophrenia in 2024. However, the industry faces significant unmet needs, with many patients experiencing refractory seizures or inadequate control of psychosis symptoms, often requiring polypharmacy. Ovid's focus on differentiated small molecule medicines targeting fundamental biological targets like GABA-AT and KCC2 positions it to address these gaps, but it must contend with larger, more resourced competitors like UCB, Jazz Pharmaceuticals, and Acadia Pharmaceuticals. The discontinuation of Takeda's soticlestat program highlights the inherent high risk of late-stage drug development in this sector.

Comparison to Industry Standards

• Ovid's OV329, a next-generation GABA-AT inhibitor, aims to offer improved efficacy and safety profiles compared to existing therapeutics like vigabatrin (VGB). Preclinical data showing OV329 is 100-fold more potent than VGB and does not accumulate in the retina, unlike VGB which has known ocular toxicity, suggests a potentially best-in-class profile.
• The KCC2 direct activator portfolio, including OV4071, is presented as unique, with Ovid stating it is the only company holding such a portfolio. This differentiates it from competitors like Axonis Therapeutics, Inc., which is developing KCC2 potentiators, implying a potentially distinct mechanism and clinical effect.
• The discontinuation of soticlestat by Takeda after failing Phase 3 endpoints is a common industry risk, demonstrating the high failure rate even for promising candidates in late-stage development, comparable to other biopharmaceutical companies facing clinical trial setbacks.
• The global market for epilepsy and antipsychotic therapies is substantial, with recent acquisitions in the range of $2.6 billion to $14.6 billion, indicating significant industry interest and potential for successful drug candidates.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Dr. Jeremy M. Levin, the Executive Chairman, purchased 71 shares of Series B Preferred Stock, 47,333 Series A Warrants, and 35,500 Series B Warrants for approximately $99,000 in the October 2025 private placement.
• Takeda Pharmaceutical Company Limited, a greater than 5% stockholder, has agreed to standstill provisions, restrictions on selling/transferring shares, voting obligations, and limitations on the percentage of outstanding common stock it may own, as per the RLT Agreement.

Stakeholder Impact

• Shareholders face potential for dilution from recent and future equity financings and warrant exercises. Market price volatility is a significant risk. The discontinuation of the soticlestat program by Takeda negatively impacted the stock price. Anti-takeover provisions and concentrated ownership may limit influence on corporate decisions.
• Employees: Organizational restructuring in 2024 led to reduced payroll expenses, implying layoffs. The company emphasizes employee engagement, development, and retention, and offers equity incentive plans.
• Customers (future patients): Development of new small molecule medicines for brain disorders aims to address significant unmet medical needs, potentially offering more efficacious and/or safer treatment options.
• Creditors: The company's ability to raise additional capital and achieve profitability will impact its ability to meet future debt obligations.
• Suppliers/Contract Manufacturers: Reliance on third parties for manufacturing and clinical trials means their performance directly impacts the company's development timelines and success.

Next Steps

• Initiate a Phase 1 clinical study for OV4071 in the second quarter of 2026.
• Conduct a ketamine challenge study for OV4071 in mid-2026 to characterize pharmacodynamic effects and establish proof-of-mechanism.
• Initiate a POC safety and signal-finding study for OV329 in Tuberous Sclerosis Complex (TSC) as early as Q4 2026.
• Continue ongoing infant formulation and enabling studies for OV329 in Infantile Spasms (IS).
• Run OV329 studies in TSC and IS in parallel to the Focal Onset Seizures (FOS) program.
• File regulatory submissions for human trials annually for successive programs emerging from the KCC2 portfolio over the next three years.
• Potentially pursue out-bound business development to partner compounds in non-core indications or extend regional market rights outside the United States.
• Build focused capabilities to commercialize programs as pipeline assets advance in the clinic.
• The Series A Warrants will expire on April 17, 2026, if not exercised in full.
• The closing of the 2026 Private Placement is expected to occur on March 19, 2026.

Key Dates

Recommendation

Ovid Therapeutics has shown improved financial performance with a reduced net loss and increased cash reserves, bolstered by successful capital raises. The progress of OV329 and OV4071 into clinical stages, with promising preclinical data and a differentiated mechanism of action, presents significant long-term potential in areas of high unmet medical need. However, the company remains in early-stage development with no commercialized products, faces substantial competition, and has experienced a major program discontinuation (soticlestat). The inherent risks of drug development, market volatility, and the need for continuous capital raises suggest a 'hold' recommendation. Investors should monitor clinical trial results, regulatory approvals, and further financial stability before considering a stronger position.

Keywords

Biopharmaceutical, Brain Disorders, Neurology, Epilepsy, Psychosis, OV329, OV4071, GABA-AT inhibitor, KCC2 direct activator, Clinical Trials, Drug Development, Capital Raise, Warrants, Neurotherapeutics, Rare Diseases, Orphan Drugs, SEC Filing, 10-K